Mesenchymal stem cell treatment for hemophilia: A review of current knowledge

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S161-S166

  Sokal, E M ^a   Lombard, C ^b   Mazza, G ^c  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Exosomes; Hemophilia A; Inborn errors; Liver; Metabolism; Stem cells

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; F8 PROTEIN, HUMAN;

ALLOGENEIC STEM CELL TRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL VACUOLE; HEMOPHILIA; HUMAN; IMMUNOMODULATION; LIVER CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; STEADY STATE; TARGET CELL; THERAPY EFFECT; ANIMAL; BIOSYNTHESIS; BLOOD; EXOSOME; GENE THERAPY; GENETICS; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; LIVER; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; EXTRACELLULAR VESICLES; FACTOR IX; FACTOR VIII; GENETIC THERAPY; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HUMANS; LIVER; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TREATMENT OUTCOME;

EID: 84931432449     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12933     Document Type: Review

References (49)

1. Mannucci PM, Franchini M. Haematology clinic: haemophilia A. Hematology 2014; 19: 181-2.
2. Hoyer LW, Hemophilia A. N Engl J Med 1994; 330: 38-47.
3. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
4. Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, Kasper CK, Kernoff PBA, Levine PH, Lusher JM, Mannucci PM, Scharrer I, MacKenzie MA, Pancham N, Kuo HS, Allred RU. Human recombinant dna-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant factor VIII study group. N Engl J Med 1990; 323: 1800-5.
5. Aledort L, Ljung R, Mann K, Pipe S. Factor VIII therapy for hemophilia A: current and future issues. Expert Rev Hematol 2014; 7: 373-85.
6. Chuah MK, Evens H, VandenDriessche T. Gene therapy for hemophilia. J Thromb Haemost 2013; 11: 99-110.
7. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994-2004.
8. Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008; 140: 479-87.
9. Brown BD, Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood 2002; 100: 1133-40.
10. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. Prevalence of serum igg and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21: 704-12.
11. Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 744-9.
12. Shahani T, Covens K, Lavend'homme R, Jazouli N, Sokal E, Peerlinck K, Jacquemin M. Human liver sinusoidal endothelial cells but not hepatocytes contain FVIII. J Thromb Haemost 2013; 12: 36-42.
13. Stel HV, van der Kwast TH, Veerman EC. Detection of factor VIII/coagulant antigen in human liver tissue. Nature 1983; 303: 530-2.
14. Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 1985; 317: 729-30.
15. Do H, Healey JF, Waller EK, Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999; 274: 19587-92.
16. Follenzi A, Raut S, Merlin S, Sarkar R, Gupta S. Role of bone marrow transplantation for correcting hemophilia A in mice. Blood 2012; 119: 5532-42.
17. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
18. Sanada C, Kuo CJ, Colletti EJ, Soland M, Mokhtari S, Knovich MA, Owen J, Zanjanai ED, Porada CD, Almeida-Porada G. Mesenchymal stem cells contribute to endogenous FVIII: C production. J Cell Physiol 2013; 228: 1010-6.
19. Najimi M, Khuu DN, Lysy PA, Jazouli N, Abarca J, Sempoux C, Sokal EM. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant 2007; 16: 717-28.
20. Porada CD, Sanada C, Kuo CJ, Colletti E, Mandeville W, Hasenau J, Zanjani ED, Moot R, Doering C, Spencer HT, Almeida-Porada G. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of fviii-expressing MSC. Exp Hematol 2011; 39: 1124-35.e4.
21. Kashiwakura Y, Ohmori T, Mimuro J, Yasumoto A, Ishiwata A, Sakata A, Mandoiwa S, Inoue M, Hasegawa M, Osawa K, Sakata Y. Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor viii-deficient mice. J Thromb Haemost 2012; 10: 1802-13.
22. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012; 21(R1): R125-34.
23. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013; 12: 347-57.
24. van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012; 64: 676-705.
25. Sabin K, Kikyo N. Microvesicles as mediators of tissue regeneration. Transl Res 2014; 163: 286-95.
26. Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res 2014; 114: 345-53.
27. Turturici G, Tinnirello R, Sconzo G, Geraci F. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am J Physiol Cell Physiol 2014; 306: C621-33.
28. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, Salto-Tellez M, Timmers L, Lee CN, Menshawe R, Oakley L, Pasterkamp G, van de Kleijn DP, Lim SK. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010; 4: 214-22.
29. Levine P, McDaniel K, Francis H, Kennedy L, Alpini G, Meng F. Molecular mechanisms of stem cell therapy in alcoholic liver disease. Dig Liver Dis 2014; 46: 391-7.
30. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, Ratajczak MZ. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mrna and protein delivery. Leukemia 2006; 20: 847-56.
31. Yuana Y, Sturk A, Nieuwland R. Extracellular vesicles in physiological and pathological conditions. Blood Rev 2013; 27: 31-9.
32. Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver diseases. Pediatr Transplant 2008; 12: 6-13.
33. Jorns C, Ellis EC, Nowak G, Fischler B, Nemeth A, Strom SC, Ericzon BG. Hepatocyte transplantation for inherited metabolic diseases of the liver. J Intern Med 2012; 272: 201-23.
34. Darwish AA, Sokal E, Stephenne X, Najimi M, de Goyet Jde V, Reding R. Permanent access to the portal system for cellular transplantation using an implantable port device. Liver Transpl 2004; 10: 1213-5.
35. Dhawan A, Mitry RR, Hughes RD, Lehec S, Terry C, Bansal S, Arya R, Wade JJ, Verma A, Heaton ND, Rela M, Mieli-Vergani G. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812-4.
36. Muraca M, Gerunda G, Neri D, Vilei MT, Granato A, Feltracco P, Meroni M, Giron G, Burlina A. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002; 359: 317-8.
37. Stéphenne X, Najimi M, Sibille C, Nassogne MC, Smets F, Sokal EM. Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. Gastroenterology 2006; 130: 1317-23.
38. Stéphenne X, Debray FG, Smets F, Jazouli N, Sana G, Tondreau T, Menten R, Goffette P, Boemer F, Schoos R, Gersting W, Najimi M, Muntau AC, Goyens P, Sokal EM. Hepatocyte transplantation using the domino concept in a child with tetrabiopterin nonresponsive phenylketonuria. Cell Transplant 2012; 21: 2765-70.
39. Stéphenne X, Najimi M, Ngoc DK, Smets F, Hue L, Guigas B, Sokal EM. Cryopreservation of human hepatocytes alters the mitochondrial respiratory chain complex 1. Cell Transplant 2007; 16: 409-19.
40. Thakker R, Yang P. Mesenchymal stem cell therapy for cardiac repair. Curr Treat Options Cardiovasc Med 2014; 16: 323.
41. Song M, Heo J, Chun JY, Bae HS, Kang JW, Kang H, Cho ME, Kim SW, Shin DM, Choo MS. The paracrine effects of mesenchymal stem cells stimulate the regeneration capacity of endogenous stem cells in the repair of a bladder-outlet-obstruction-induced overactive bladder. Stem Cells Dev 2014; 23: 654-63.
42. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86.
43. Martin I, Baldomero H, Bocelli-Tyndall C, Emmert MY, Hoerstrup SP, Ireland H, Passweg J, Tyndall A. The survey on cellular and engineered tissue therapies in Europe in 2011. Tissue Eng Part A 2014; 20: 842-53.
44. Campard D, Lysy PA, Najimi M, Sokal EM. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 2008; 134: 833-48.
45. Khuu DN, Nyabi O, Maerckx C, Sokal E, Najimi M. Adult human liver mesenchymal stem/progenitor cells participate in mouse liver regeneration after hepatectomy. Cell Transplant 2013; 22: 1369-80.
46. Scheers I, Maerckx C, Khuu DN, Marcelle S, Decottignies A, Najimi M, Sokal E. Adult-derived human liver progenitor cells in long-term culture maintain appropriate gatekeeper mechanisms against transformation. Cell Transplant 2012; 21: 2241-55.
47. Defresne F, Tondreau T, Stéphenne X, Smets F, Bourgois A, Najimi M, Jamar F, Sokal EM. Biodistribution of adult derived human liver stem cells following intraportal infusion in a 17-year-old patient with glycogenosis type 1A. Nucl Med Biol 2014; 41: 371-5.
48. Sokal EM, Stéphenne X, Ottolenghi C, Jazouli N, Clapuyt P, Lacaille F, Jazouli N, Clapuyt P, Lacaille F, Najimi M, de Lonlay P, Smets F. Liver engraftment and repopulation by in vitro expanded adult derived human liver stem cells in a child with ornithine carbamoyltransferase deficiency. JIMD Rep 2014; 13: 65-72.
49. Dobbelaere D, Smets F, McKiernan P, Broué P, Dionisi-Vici C, Eyskens F, Thonnard J, de Vos B, Sokal EM. Phase I/II multicenter trial of liver derived mesenchymal stem cells for the treatment of urea cycle disorder and crigler najjar. Interim analysis at 6 months post infusion. JIMD 2014; 37: 27-185.